CDK4-R24C

CDK4-R24C is a mutant form of cyclin-dependent kinase 4, a serine/threonine kinase that plays a pivotal role in regulating the cell cycle, particularly the transition from G1 to S phase. The R24C mutation involves the substitution of arginine with cysteine at position 24, a site critical for binding to the cyclin-dependent kinase inhibitor p16INK4a. This single-point mutation is of significant interest in biochemical and cancer research due to its impact on kinase regulation, its association with tumorigenesis, and its utility in dissecting the molecular mechanisms underlying cell cycle control. The availability of this mutant protein enables researchers to explore the functional consequences of disrupted CDK4 regulation and to model disease-relevant scenarios in vitro.

Cell Cycle Regulation Studies: CDK4-R24C is widely employed in fundamental research focused on cell cycle dynamics. The R24C mutation renders the kinase resistant to inhibition by p16INK4a, allowing for unimpeded progression through the G1 checkpoint. By introducing this mutant into cell lines or in vitro systems, researchers can directly assess the effects of altered CDK4 activity on cell proliferation, checkpoint fidelity, and the broader regulatory network governing cell division. This application is particularly valuable for elucidating the interplay between cyclin D, CDK4, and endogenous inhibitors in normal and pathological contexts.

Oncogenesis and Tumor Suppressor Pathway Analysis: The R24C variant of CDK4 has been implicated in the pathogenesis of various cancers, including familial melanoma and certain sarcomas. Its resistance to p16INK4a-mediated inhibition provides a model for studying the bypass of critical tumor suppressor pathways. Scientists use this mutant protein to investigate how dysregulated CDK4 activity contributes to oncogenic transformation, facilitates unchecked cell proliferation, and interacts with other oncogenic signals. Such studies are instrumental in mapping the molecular events that drive tumorigenesis and in identifying potential vulnerabilities in cancer cells.

Drug Discovery and Inhibitor Screening: The unique properties of the CDK4-R24C mutant make it an essential tool in high-throughput screening and structure-activity relationship studies targeting cyclin-dependent kinases. By incorporating this variant into biochemical assays, researchers can evaluate the specificity and efficacy of small-molecule inhibitors designed to modulate CDK4 activity. This approach is critical for distinguishing compounds that retain activity against mutant forms of the kinase, thereby informing the development of next-generation inhibitors for research use in oncology and cell cycle regulation.

Protein-Protein Interaction Mapping: The altered binding affinity of CDK4-R24C for regulatory proteins such as p16INK4a and cyclin D1 enables detailed studies of protein-protein interactions within the cell cycle machinery. Researchers utilize this mutant to dissect the structural and functional determinants of inhibitor binding, to map interaction domains, and to analyze the consequences of disrupted regulatory complexes. These insights are valuable for understanding the molecular architecture of cell cycle regulation and for designing targeted modulators of protein interactions.

Functional Genomics and Model System Engineering: The R24C CDK4 mutant is frequently used in the generation of engineered cell lines and model organisms for functional genomics studies. By introducing this mutation, scientists can create systems that mimic the deregulated cell cycle observed in certain disease states, facilitating the investigation of downstream genetic and epigenetic changes. These models are instrumental in unraveling the broader biological consequences of CDK4 dysregulation and in validating candidate genes or pathways implicated in cell proliferation and cancer biology.

1. Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans and Candida albicans Clinical Isolates from Children with Early Childhood Caries

2. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

3. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

4. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

5. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients